{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Pleural+Mesotheliomas", "query": { "condition": "Malignant Pleural Mesotheliomas" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 194, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Pleural+Mesotheliomas&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T06:04:08.090Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03420963", "title": "Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Cutaneous Melanoma", "Recurrent Lip and Oral Cavity Carcinoma", "Recurrent Malignant Endocrine Neoplasm", "Recurrent Malignant Female Reproductive System Neoplasm", "Recurrent Malignant Male Reproductive System Neoplasm", "Recurrent Malignant Mesothelioma", "Recurrent Malignant Neoplasm of Multiple Primary Sites", "Recurrent Malignant Oral Neoplasm", "Recurrent Malignant Pharyngeal Neoplasm", "Recurrent Malignant Skin Neoplasm", "Recurrent Malignant Soft Tissue Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Malignant Thyroid Gland Neoplasm", "Recurrent Malignant Urinary System Neoplasm", "Refractory Cutaneous Melanoma", "Refractory Malignant Bone Neoplasm", "Refractory Malignant Endocrine Neoplasm", "Refractory Malignant Female Reproductive System Neoplasm", "Refractory Malignant Male Reproductive System Neoplasm", "Refractory Malignant Mesothelioma", "Refractory Malignant Neoplasm of Multiple Primary Sites", "Refractory Malignant Oral Neoplasm", "Refractory Malignant Pharyngeal Neoplasm", "Refractory Malignant Skin Neoplasm", "Refractory Malignant Soft Tissue Neoplasm", "Refractory Malignant Solid Neoplasm", "Refractory Malignant Thyroid Gland Neoplasm", "Refractory Malignant Urinary System Neoplasm" ], "interventions": [ { "name": "Cord Blood-derived Expanded Allogeneic Natural Killer Cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "40 Years", "sex": "ALL", "summary": "12 Months to 40 Years" }, "enrollment_count": 12, "start_date": "2018-08-31", "completion_date": "2026-02-26", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-07-22T06:04:08.090Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03420963" }, { "nct_id": "NCT04515836", "title": "Olaparib in Patients With HRD Malignant Mesothelioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mesothelioma", "Homologous Recombination Deficiency" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2021-02-19", "completion_date": "2028-04-15", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-07-22T06:04:08.090Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04515836" }, { "nct_id": "NCT02611037", "title": "Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Pleural Mesothelioma", "Mesothelioma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Lung Cancer Symptom Scale for Mesothelioma Questionnaire", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2016-03-04", "completion_date": "2024-01-26", "has_results": true, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-07-22T06:04:08.090Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02611037" }, { "nct_id": "NCT02592551", "title": "MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "MEDI4736", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "no other name", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-05-11", "completion_date": "2022-09-01", "has_results": true, "last_update_posted_date": "2022-09-29", "last_synced_at": "2026-07-22T06:04:08.090Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02592551" }, { "nct_id": "NCT05563272", "title": "89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer", "Colorectal Cancer", "Esophageal Cancer", "Gastric Cancer", "Glioblastoma Multiforme", "Cholangiocarcinoma", "Hepatocellular Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Nasopharyngeal Carcinoma", "Non Small Cell Lung Cancer", "Small Cell Lung Cancer", "Epithelial Ovarian Cancer", "Pancreatic Ductal Adenocarcinoma", "Soft Tissue Sarcoma", "Gastric Adenocarcinoma", "Malignant Mesothelioma (MM)", "Von Hippel Lindau", "Bladder Cancer", "Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "89Zr-girentuximab for PET/CT imaging of CAIX positive tumors", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Telix Pharmaceuticals (Innovations) Pty Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 11, "start_date": "2023-06-06", "completion_date": "2025-05-09", "has_results": false, "last_update_posted_date": "2025-07-10", "last_synced_at": "2026-07-22T06:04:08.090Z", "location_count": 10, "location_summary": "Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Traverse City", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05563272" }, { "nct_id": "NCT04981119", "title": "Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "Non Small Cell Lung Cancer", "Pancreatic Cancer", "CRC", "NSCLC", "Pancreas Cancer", "Mesothelioma", "Ovarian Cancer", "Ovarian Neoplasms", "Ovarian Carcinoma", "Mesothelioma, Malignant", "Mesothelioma; Lung", "Cancer", "Triple Negative Breast Cancer (TNBC)", "Renal Cell Carcinoma (Kidney Cancer)", "Head and Neck Squamous Cell Carcinoma HNSCC" ], "interventions": [ { "name": "Apheresis", "type": "OTHER" }, { "name": "Next Generation Sequencing (NGS)", "type": "DIAGNOSTIC_TEST" }, { "name": "Long Range NGS HLA typing", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2021-10-29", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-07-22T06:04:08.090Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04981119" }, { "nct_id": "NCT00053885", "title": "PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Mesothelioma" ], "interventions": [ { "name": "PTK787/ZK 222584", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2003-07", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2016-07-01", "last_synced_at": "2026-07-22T06:04:08.090Z", "location_count": 80, "location_summary": "Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 58 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053885" }, { "nct_id": "NCT02399371", "title": "Pembrolizumab in Treating Patients With Malignant Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Biphasic Mesothelioma", "Epithelioid Mesothelioma", "Peritoneal Malignant Mesothelioma", "Pleural Biphasic Mesothelioma", "Pleural Epithelioid Mesothelioma", "Pleural Malignant Mesothelioma", "Pleural Sarcomatoid Mesothelioma", "Recurrent Peritoneal Malignant Mesothelioma", "Recurrent Pleural Malignant Mesothelioma", "Sarcomatoid Mesothelioma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-03-31", "completion_date": "2026-03-20", "has_results": true, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-07-22T06:04:08.090Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02399371" }, { "nct_id": "NCT03683680", "title": "Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "MPT Test", "type": "OTHER" }, { "name": "CLDN15/VIM Test", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2018-10-31", "completion_date": "2030-10-01", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-07-22T06:04:08.090Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03683680" }, { "nct_id": "NCT03126630", "title": "Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pleural Malignant Mesothelioma" ], "interventions": [ { "name": "Anetumab Ravtansine", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-10-04", "completion_date": "2027-02-25", "has_results": true, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-07-22T06:04:08.090Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03126630" } ] }